TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #15621 · Apr 15

#shell#ai_agents#ai_assisted_development#anthropic#claude#claude_code#game_design#game_development#gamedev#godot#indie_game_dev#unity#unreal_engine Claude Code Game Studios turns one Claude Code session into a full game dev team with 49 specialized agents, 72 skills, 12 hooks, and 11 rules for engines like Godot, Unity, and Unreal. Use slash commands like `/start`, `/brainstorm`, or `/dev-story` for design, coding, QA, and release—agents ask questions, show options, and get your approval to stay organized. You benefit by building games solo with pro structure, catching errors early, and shipping faster without chaos. https://github.com/Donchitos/Claude-Code-Game-Studios

Results

3 similar posts found

Search: #clinicalstage

当前筛选 #clinicalstage清除筛选
Venture Village Wall 🦄

@venturevillagewall · Post #3534 · 12/20/2024, 09:31 AM

$2.16M Fundraising by Umecrine Umecrine Cognition, a Swedish clinical-stage pharmaceutical firm, has raised $2.16 million to advance its innovative drug development targeting neurological disorders. The funding round took place on December 19, 2024. #UmecrineCognition#Pharmaceuticals#NeurologicalDisorders#Funding#Healthcare#ClinicalStage#Sweden

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3412 · 12/18/2024, 12:11 PM

$60M Funding for Psioxus Psioxus Therapeutics has successfully secured $60M in funding as part of its latest round, scheduled for December 17, 2024. This funding aims to advance its innovative tumor gene therapy platform focused on improving cancer treatment outcomes. #Funding#Cancer#Biotech#Oncology#GeneTherapy#Therapeutics#ClinicalStage#Investment#Healthcare#Psioxus#AkamisBio#Tumor#LifeScience#MedicalResearch#Therapy#Innovative#Impact#Technology#Platform